Trials / Completed
CompletedNCT03165071
A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease
A Single-center, Open Label, Single-dose Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics of ACT-132577
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to investigate the fate of ACT-132577 in healthy subjects and in people with severe kidney disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-132577 | Capsule |
Timeline
- Start date
- 2017-06-03
- Primary completion
- 2017-10-27
- Completion
- 2017-10-27
- First posted
- 2017-05-24
- Last updated
- 2022-11-23
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT03165071. Inclusion in this directory is not an endorsement.